The unintended consequences of small molecules
Podcast: BioSpacePublished On: Thu Mar 14 2024
Description: Continuing on from our previous episode "The gap is where the pain is", this episode focuses on a healthy discussion regarding the IRA, particularly the unintended consequences to small molecule development within the industry and for patients. Topics explored in this discussion are potential reasons behind the small molecule negotiation timeline decision, the antibody drug conjugates (ADC) boom, the investment environment, and positive steps the government is making through legislation to equalize the negotiation timeline. Host Lori Ellis, Head of Insights, BioSpace Guests Ali Pashazadeh, CEO,Treehill Partners Dan Smithey, President, CEO and Co-founder, Serán BioScience Matthew Price, COO and Co-founder, Promontory Therapeutics Peter Rubin, Executive Director, No Patient Left Behind Rob Williamson, President and COO, Triumvira Immunologics
The note was deleted
The note was saved
Your message was sent